- Home
- ABT
as 07-26-2024 4:00pm EST
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
| Founded: | 1888 | Country: | United States |
| Employees: | N/A | City: | ABBOTT PARK |
| Market Cap: | 177.5B | IPO Year: | N/A |
| Target Price: | $122.30 | AVG Volume (30 days): | 6.8M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 3.21 | EPS Growth: | -2.43 |
| 52 Week Low/High: | $89.67 - $121.64 | Next Earning Date: | 07-18-2024 |
| Revenue: | $40,326,000,000 | Revenue Growth: | -2.84% |
| Revenue Growth (this year): | 5.11% | Revenue Growth (next year): | 7.28% |
Stock Insider Trading Activity of Abbott Laboratories (ABT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Funck, Jr. Robert E. | ABT | EXECUTIVE VICE PRESIDENT | May 10 '24 | Sell | $104.57 | 10,097 | $1,055,819.06 | 211,341 | SEC Form 4 |
| Earnhardt Lisa D | ABT | EXECUTIVE VICE PRESIDENT | May 7 '24 | Sell | $106.25 | 22,852 | $2,428,118.69 | 61,462 | SEC Form 4 |
| Salvadori Daniel Gesua Sive | ABT | EXECUTIVE VICE PRESIDENT | Feb 29 '24 | Sell | $118.50 | 963 | $114,115.50 | 125,697 | SEC Form 4 |
| Morrone Louis H. | ABT | EXECUTIVE VICE PRESIDENT | Feb 29 '24 | Sell | $118.50 | 801 | $94,918.50 | 62,968 | SEC Form 4 |
| Earnhardt Lisa D | ABT | EXECUTIVE VICE PRESIDENT | Feb 29 '24 | Sell | $118.50 | 694 | $82,239.00 | 84,314 | SEC Form 4 |
| ALLEN HUBERT L | ABT | EXECUTIVE VICE PRESIDENT | Feb 29 '24 | Sell | $118.50 | 853 | $101,080.50 | 184,806 | SEC Form 4 |
| MCCOY JOHN A. JR. | ABT | VICE PRESIDENT | Feb 29 '24 | Sell | $118.50 | 472 | $55,932.00 | 18,760 | SEC Form 4 |
| Moreland Mary K | ABT | EXECUTIVE VICE PRESIDENT | Feb 29 '24 | Sell | $118.50 | 676 | $80,106.00 | 91,260 | SEC Form 4 |
| Wainer Andrea F | ABT | EXECUTIVE VICE PRESIDENT | Feb 23 '24 | Sell | $120.00 | 12,500 | $1,500,000.00 | 78,704 | SEC Form 4 |
| Wainer Andrea F | ABT | EXECUTIVE VICE PRESIDENT | Jan 29 '24 | Sell | $112.50 | 25,000 | $2,812,500.00 | 65,027 | SEC Form 4 |
| Wainer Andrea F | ABT | EXECUTIVE VICE PRESIDENT | Jan 29 '24 | Sell | $112.50 | 17,500 | $1,968,750.00 | 65,027 | SEC Form 4 |
| Wainer Andrea F | ABT | EXECUTIVE VICE PRESIDENT | Dec 14 '23 | Sell | $108.00 | 15,000 | $1,620,000.00 | 65,027 | SEC Form 4 |
| STARKS DANIEL J | ABT | Director | Oct 26 '23 | Sell | $93.81 | 26,907 | $2,524,255.99 | 6,748,409 | SEC Form 4 |
| STARKS DANIEL J | ABT | Director | Oct 26 '23 | Sell | $94.33 | 23,093 | $2,178,270.32 | 6,725,316 | SEC Form 4 |
Latest Abbott Laboratories News
ABT Breaking Stock News: Dive into ABT Ticker-Specific Updates for Smart Investing
Zacks
7 hours ago
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
Zacks
11 hours ago
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
Motley Fool
15 hours ago
Better Buy: Abbott Laboratories vs. Intuitive Surgical
The Wall Street Journal
a day ago
S&P 500’s Biggest Loser Has a Heart Valve Problem
Zacks
a day ago
The Zacks Analyst Blog Highlights SAP, Abbott Laboratories, Citigroup, Team and Vaso
Motley Fool
2 days ago
3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years
Zacks
2 days ago
Top Analyst Reports for SAP, Abbott Laboratories & Citigroup
MT Newswires
2 days ago
Daiwa Securities Adjusts Price Target on Abbott Laboratories to $120 From $125
Compare ABT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABT Abbott Laboratories - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.